Castle Biosciences Inc. (CSTL) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Castle Biosciences’s revenue went from $23M in fiscal 2018 to $344M in fiscal 2025, growth of about 47.4% a year.
Net income in fiscal 2025 was -$24M, a net margin of -7.0%; the best year in this period was 2024 with $18M.
Over the twelve months to September 30, 2026, revenue was $377M and net income -$23M.
Free cash flow was $28M in fiscal 2025 and positive in 4 of the 8 years shown.
The diluted share count rose 1421% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $377M | $344M | $332M | $220M | $137M | $94M | $63M | $52M | $23M |
| Gross profit | $291M | $273M | $272M | $175M | $105M | $78M | $53M | $45M | $17M |
| Operating income | -$28M | -$43M | $9M | -$68M | -$73M | -$40M | -$7M | $7M | -$4M |
| Net income | -$23M | -$24M | $18M | -$57M | -$67M | -$31M | -$10M | $5M | -$6M |
| EPS (diluted) | $-0.76 | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $-0.21 | $-5.33 |
| R&D | $58M | $52M | $52M | $54M | $45M | $30M | $13M | $7M | $5M |
| Revenue growth | — | +3.7% | +51.1% | +60.4% | +45.6% | +50.2% | +20.8% | +127.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $40M | $64M | $65M | -$6M | -$42M | -$19M | $10M | $7M | -$12M |
| Capital spending | -$36M | -$36M | -$28M | -$14M | -$6M | -$3M | -$5M | -$937000 | -$277000 |
| Free cash flow | $4M | $28M | $37M | -$19M | -$47M | -$22M | $5M | $6M | -$13M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $44M | $46M | $50M | $51M | $36M | $22M | $8M | $1M | $294000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $300M | $293M | $243M | $259M | $330M | $410M | $99M | $4M |
| Debt | — | $37M | $26M | $15M | $13M | $8M | $0 | $27M | $24M |
| Equity | — | $471M | $456M | $391M | $399M | $412M | $416M | $85M | -$57M |
| Total assets | — | $579M | $531M | $453M | $447M | $463M | $439M | $120M | $22M |
| Shares (diluted) | 31M | 29M | 29M | 27M | 26M | 25M | 19M | 9M | 2M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 77.1% | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% |
| Operating margin | -7.4% | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | -10.4% | 14.1% | -16.8% |
| Net margin | -6.1% | -7.0% | 5.5% | -26.2% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% |
| FCF margin | 1.1% | 8.2% | 11.0% | -8.8% | -34.5% | -23.9% | 8.2% | 11.7% | -55.2% |
| ROIC | — | -6.7% | 1.4% | -13.2% | -14.0% | -7.5% | -1.2% | 5.2% | — |
| ROE | — | -5.1% | 4.0% | -14.7% | -16.8% | -7.6% | -2.5% | 6.2% | 11.3% |
Frequently asked questions
What is Castle Biosciences’s annual revenue?
$344M in fiscal 2025 and $377M over the twelve months to September 30, 2026.
How much profit does Castle Biosciences make?
Net income was -$24M in fiscal 2025 (net margin -7.0%).
Is Castle Biosciences’s revenue growing?
Yes: revenue rose 3.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.